CommercialCoverageMedium impact
08.01.36e, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross·Pharmacy, Neurology, Pediatrics·Pharmacy
Effective date
Oct 2, 2024
We identified it
Jun 19, 2026
Summary
This policy reissue (effective 10/02/2024) addresses coverage and billing requirements for two spinal muscular atrophy (SMA) therapies: Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®). The billing team must review the specific coverage criteria, prior authorization requirements, and pharmacy billing codes for these specialty medications to ensure compliant claim submission.
Action Required
By 01/17/2025: Billing team and pharmacy staff must obtain and review the complete policy text at the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-36e) to extract specific HCPCS codes, prior authorization requirements, and medical necessity criteria for Spinraza® and Zolgensma®. Update billing system rules and prior authorization workflows accordingly. Flag any claims for these therapies submitted before policy implementation (10/02/2024) for review and potential resubmission. Ensure pharmacy and clinical staff understand coverage limitations and documentation requirements. Failure to follow updated requirements will result in claim denials and potential payment recoupments.